Full Accounting of Diabetes and Pre-diabetes in the U.S. Population in 1988-1994 and 2005-2006
Overview
Authors
Affiliations
Objective: We examined the prevalences of diagnosed diabetes, and undiagnosed diabetes and pre-diabetes using fasting and 2-h oral glucose tolerance test values, in the U.S. during 2005-2006. We then compared the prevalences of these conditions with those in 1988-1994.
Research Design And Methods: In 2005-2006, the National Health and Nutrition Examination Survey included a probability sample of 7,267 people aged > or =12 years. Participants were classified according to glycemic status by interview for diagnosed diabetes and by fasting and 2-h glucoses measured in subsamples.
Results: In 2005-2006, the crude prevalence of total diabetes in people aged > or =20 years was 12.9%, of which approximately 40% was undiagnosed. In people aged > or =20 years, the crude prevalence of impaired fasting glucose was 25.7% and of impaired glucose tolerance was 13.8%, with almost 30% having either. Over 40% of individuals had diabetes or pre-diabetes. Almost one-third of the elderly had diabetes, and three-quarters had diabetes or pre-diabetes. Compared with non-Hispanic whites, age- and sex-standardized prevalence of diagnosed diabetes was approximately twice as high in non-Hispanic blacks (P < 0.0001) and Mexican Americans (P = 0.0001), whereas undiagnosed diabetes was not higher. Crude prevalence of diagnosed diabetes in people aged > or =20 years rose from 5.1% in 1988-1994 to 7.7% in 2005-2006 (P = 0.0001); this was significant after accounting for differences in age and sex, particularly in non-Hispanic blacks. Prevalences of undiagnosed diabetes and pre-diabetes were generally stable, although the proportion of total diabetes that was undiagnosed decreased in Mexican Americans.
Conclusions: Over 40% of people aged > or =20 years have hyperglycemic conditions, and prevalence is higher in minorities. Diagnosed diabetes has increased over time, but other conditions have been relatively stable.
Cytokines in age-related eye diseases: pathogenesis and potential targets for innovative therapies.
Zhang T, Liu M Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40021512 DOI: 10.1007/s00210-025-03926-1.
Shahrestanaki E, Mohammadian Khonsari N, Seif E, Baygi F, Ejtahed H, Sheidaei A Front Public Health. 2024; 12:1305304.
PMID: 38827607 PMC: 11140097. DOI: 10.3389/fpubh.2024.1305304.
Sanjari E, Raeisi Shahraki H, Khachatryan L, Mohammadian-Hafshejani A PLoS One. 2024; 19(4):e0299442.
PMID: 38626071 PMC: 11020394. DOI: 10.1371/journal.pone.0299442.
Bauvin P, Delacote C, Wandji L, Lassailly G, Raverdy V, Pattou F PLoS One. 2024; 19(3):e0301463.
PMID: 38547299 PMC: 10977742. DOI: 10.1371/journal.pone.0301463.
Silva F, Duarte-Mendes P, Teixeira A, Soares C, Ferreira J Sci Rep. 2024; 14(1):1936.
PMID: 38253590 PMC: 10803738. DOI: 10.1038/s41598-024-51832-y.